OLAPLEX Reports Fourth Quarter and Fiscal Year 2025 Results

NEW YORK, NY, March 05, 2026 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (NASDAQ: OLPX) ("OLAPLEX" or the "Company") today announced financial results for the fourth quarter and fiscal year ended December 31, 2025.

Amanda Baldwin, OLAPLEX’s Chief Executive Officer, commented: "We ended 2025 on a high note with fourth quarter sales growth of 4.3%. In 2025, we delivered on our Bonds & Beyond transformation priorities, driving renewed brand momentum and building a consistent innovation pipeline while strengthening execution and sharpening strategic focus. As we enter 2026, we do so with a clear path forward and a more balanced, sustainable approach to investment and growth."

For the fourth quarter of 2025 compared to the fourth quarter of 2024 :

  • Net sales increased 4.3% to $105.1 million;
    • By channel:
      • Specialty Retail decreased 14.5% to $24.7 million;
      • Professional increased 18.9% to $36.8 million;
      • Direct-To-Consumer increased 6.6% to $43.6 million;
    • Net sales increased 0.8% in the United States and increased 7.6% internationally;
  • Net loss was $13.1 million, as compared to $8.8 million for the fourth quarter of 2024;
  • Diluted net loss per share was $(0.02), as compared to $(0.01) for the fourth quarter of 2024.

For the fiscal year 2025 compared to the fiscal year 2024 :

  • Net sales increased 0.1% to $423.0 million;
    • By channel:
      • Specialty Retail decreased 8.3% to $130.4 million;
      • Professional increased 5.5% to $153.3 million;
      • Direct-To-Consumer increased 3.1% to $139.3 million;
  • Net loss was $9.3 million, as compared to net income of $19.5 million for 2024;
  • Diluted net (loss) income per share was $(0.01), as compared to $0.03 for 2024.

Three Months Ended December 31, 2025 Results

(Amounts in thousands, except per share data)          
  Three Months Ended December 31,    
    2025       2024     % Change
Net Sales $ 105,119     $ 100,741     4.3%
Gross Profit $ 71,457     $ 66,776     7.0%
Gross Profit Margin   68.0 %     66.3 %    
Adjusted Gross Profit $ 74,162     $ 69,064     7.4%
Adjusted Gross Profit Margin   70.6 %     68.6 %    
SG&A $ 65,107     $ 52,869     23.1%
Adjusted SG&A $ 61,415     $ 50,306     22.1%
Net Loss $ (13,102 )   $ (8,800 )   48.9%
Adjusted Net Income $ 5,560     $ 7,630     (27.1)%
Adjusted EBITDA $ 12,861     $ 17,489     (26.5)%
Adjusted EBITDA Margin   12.2 %     17.4 %    
Diluted Net Loss Per Share $ (0.02 )   $ (0.01 )   100.0%
Adjusted Diluted Net Income Per Share $ 0.01     $ 0.01     —%


Fiscal Year 2025 Results

(Amounts in thousands, except per share data)          
  Year Ended December 31,    
    2025       2024     % Change
Net Sales $ 422,960     $ 422,670     0.1%
Gross Profit $ 293,646     $ 292,290     0.5%
Gross Profit Margin   69.4 %     69.2 %    
Adjusted Gross Profit $ 303,631     $ 301,632     0.7%
Adjusted Gross Profit Margin   71.8 %     71.4 %    
SG&A $ 243,113     $ 181,685     33.8%
Adjusted SG&A $ 211,375     $ 170,550     23.9%
Net (Loss) Income $ (9,252 )   $ 19,522     (147.4)%
Adjusted Net Income $ 51,383     $ 75,713     (32.1)%
Adjusted EBITDA $ 93,869     $ 129,665     (27.6)%
Adjusted EBITDA Margin   22.2 %     30.7 %    
Diluted Net (Loss) Income Per Share $ (0.01 )   $ 0.03     (133.3)%
Adjusted Diluted Net Income Per Share $ 0.08     $ 0.11     (27.3)%


Adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income, adjusted EBITDA, adjusted EBITDA margin and adjusted diluted net income per share are measures that are not calculated or presented in accordance with generally accepted accounting principles in the United States of America ("GAAP"). For more information about how we use these non-GAAP financial measures in our business, the limitations of these measures, and a reconciliation of these measures to the most directly comparable GAAP measures, please see "Disclosure Regarding Non-GAAP Financial Measures" and the reconciliation tables that accompany this release.

Balance Sheet

As of December 31, 2025, the Company had $318.7 million of cash and cash equivalents, compared to $586.0 million as of December 31, 2024. Inventory at the end of the fourth quarter of 2025 was $60.2 million, compared to $75.2 million at December 31, 2024. Long-term debt, net of current portion and deferred debt issuance costs was $352.3 million as of December 31, 2025, compared to $643.7 million as of December 31, 2024.

Fiscal Year 2026 Guidance

The Company's fiscal year 2026 guidance below assumes no material impact from tariffs or the current geopolitical environment. The fiscal year 2026 net sales guidance below also reflects management's expectation that the net sales performance for the first quarter will trend below the expected net sales performance for the full fiscal year 2026, on a percentage basis, with consumer demand expected to be weighted towards the second half of the year as strategic initiatives take effect. Further, management expects that adjusted EBITDA margin in the first quarter will trend significantly below the expected adjusted EBITDA margin for the full fiscal year 2026, as marketing spend is expected to be front loaded in fiscal year 2026.

For Fiscal 2026:    
(Dollars in millions) 2026 2025 Actual
Net Sales $414 - $435 $423
Adjusted Gross Profit Margin* 71% to 72% 71.8%
Adjusted EBITDA Margin* 21% to 22% 22.2%

*Adjusted gross profit margin and adjusted EBITDA margin are non-GAAP measures. See “Disclosure Regarding Non-GAAP Financial Measures” for additional information.

Webcast and Conference Call Information

The Company plans to host an investor conference call and webcast to review fourth quarter and fiscal 2025 financial results at 9:00am ET/6:00am PT on March 5, 2026. The webcast can be accessed at https://ir.olaplex.com. The conference call can be accessed by calling (201) 689-8521 or (877) 407-8813 for a toll-free number. A replay of the webcast will remain available on the website for 90 days.

About OLAPLEX

OLAPLEX is a foundational health and beauty company powered by breakthrough innovation and the professional hairstylist. Born in the lab and brought to the chair, our products are designed to enable Pros and their clients to achieve their best results and to provide consumers with a holistic healthy hair regimen. Founded in 2014, OLAPLEX revolutionized prestige hair care with its category creating Complete Bond Technology™, which works by protecting, strengthening and relinking all three bonds during and after hair services. Since then, OLAPLEX has expanded into a full suite of hair health formulas. OLAPLEX’s award-winning products are sold globally through an omnichannel model serving the professional, specialty retail, and direct-to-consumer channels.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by, and information currently available to, the Company. These forward-looking statements include, but are not limited to, statements about: the Company’s financial position, operating results, growth, sales and profitability, including revenue shifts across channels; the Company's financial guidance for fiscal year 2026, including net sales, adjusted gross profit margin and adjusted EBITDA margin; the Company's expectations regarding net sales and adjusted EBITDA margin for the first quarter 2026; the Company's financial position, profitability, sell-through, operating expenses and growth; demand for the Company’s products; the Company’s innovation strategy and pipeline; the Company's international strategy and operations; the Company’s business transformation plans, strategies, investments, priorities and objectives, including the impact and timing thereof; the Company's packaging redesign initiative; the Company's capital allocation opportunities; the Company’s sales, marketing, promotion and education initiatives and related investments, and the impact, focus and timing thereof; general economic and industry trends, including tariffs; sales channels; inventory levels; and other statements contained in this press release that are not historical or current facts. When used in this press release, words such as "may," "will," “could," "should," "intend," "potential," "continue," "anticipate," "believe," "estimate," "expect," "plan," "target," "predict," "project," "forecast," "seek" and similar expressions as they relate to the Company are intended to identify forward-looking statements.

The forward-looking statements in this press release reflect the Company’s current expectations and projections about future events and financial trends that management believes may affect the Company’s business, financial condition and results of operations. These statements are predictions based upon assumptions that may not prove to be accurate, and they are not guarantees of future performance. As such, you should not place significant reliance on the Company’s forward-looking statements. Neither the Company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements, including any such statements taken from third party industry and market reports.

Forward-looking statements involve known and unknown risks, inherent uncertainties and other factors that are difficult to predict which may cause the Company’s actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements, including, without limitation: the Company’s dependence on the success of its business transformation plan; competition in the beauty industry; the Company’s ability to effectively maintain and promote a positive brand image, expand its brand awareness and maintain consumer confidence in the quality, safety and efficacy of its products; the Company’s ability to anticipate and respond to market trends and changes in consumer preferences and execute on its growth strategies and expansion opportunities, including with respect to new product introductions; the Company’s ability to develop, manufacture and effectively and profitably market and sell future products; the Company’s ability to attract new customers and consumers and encourage consumer spending across its product portfolio; the Company’s ability to successfully implement new or additional marketing efforts; the Company’s relationships with and the capabilities and performance of its suppliers, manufacturers, distributors and retailers and the Company’s ability to manage its supply chain, including sourcing, manufacturing and quality control; the Company's dependence on a limited number of customers for a large portion of its net sales; the Company’s ability to limit the illegal distribution and sale by third parties of counterfeit versions of its products or the unauthorized diversion by third parties of its products; the Company’s ability to accurately forecast customer and consumer demand for its products; impacts on the Company’s business from political, regulatory, economic, trade and other risks associated with operating internationally; the Company’s ability to attract and retain senior management and other qualified personnel; the Company’s reliance on its and its third-party service providers’ information technology; the Company’s ability to maintain the security of confidential information; the Company’s ability to establish and maintain intellectual property protection for its products, as well as the Company’s ability to operate its business without infringing, misappropriating or otherwise violating the intellectual property rights of others; the outcome of litigation and regulatory proceedings; the impact of changes in federal, state and international laws, regulations and administrative policy, tariffs and other trade policies; the Company’s existing and any future indebtedness, including the Company’s ability to comply with affirmative and negative covenants under its credit agreement; the Company’s ability to service its existing indebtedness and obtain additional capital to finance operations and its growth opportunities; volatility of the Company’s stock price; the Company’s “controlled company” status and the influence of investment funds affiliated with Advent International, L.P. over the Company; the impact of general economic conditions, disruptions in business conditions, and the financial strength of the Company’s consumers and customers on the Company’s business; fluctuations in the Company’s quarterly results of operations; changes in the Company’s tax rates and the Company’s exposure to tax liability; the Company's ability to integrate or realize the intended benefits of its acquisitions or strategic investments; and the other factors identified under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") and in the other documents that the Company files with the SEC from time to time.

Many of these factors are macroeconomic in nature and are, therefore, beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in this press release as anticipated, believed, estimated, expected, intended, planned or projected. The forward-looking statements in this press release represent management’s views as of the date hereof. Unless required by law, the Company neither intends nor assumes any obligation to update these forward-looking statements for any reason after the date hereof to conform these statements to actual results or to changes in the Company’s expectations or otherwise.

Disclosure Regarding Non-GAAP Financial Measures

In addition to the financial measures presented in this release in accordance with GAAP, the Company has included certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income and adjusted basic and diluted net income per share. Management believes these non-GAAP financial measures, when taken together with the Company’s financial results presented in accordance with GAAP, provide meaningful supplemental information regarding the Company’s operating performance and facilitate internal comparisons of its historical operating performance on a more consistent basis by excluding certain items that may not be indicative of its business, results of operations or outlook. In particular, management believes that the use of these non-GAAP measures may be helpful to investors as they are measures used by management in assessing the health of the Company’s business, determining incentive compensation and evaluating its operating performance, as well as for internal planning and forecasting purposes.

The Company calculates adjusted EBITDA as net income (loss), adjusted to exclude: (1) interest expense, net; (2) income tax provision (benefit); (3) depreciation and amortization; (4) share-based compensation expense; (5) certain litigation-related expenses; (6) acquisition-related costs; (7) executive reorganization costs and (8) Tax Receivable Agreement liability adjustments. The Company calculates adjusted EBITDA margin by dividing adjusted EBITDA by net sales. The Company calculates adjusted gross profit as gross profit, adjusted to exclude amortization of patented formulations. The Company calculates adjusted gross profit margin by dividing adjusted gross profit by net sales. The Company calculates adjusted SG&A as SG&A, adjusted to exclude: (1) share-based compensation expense; (2) certain litigation-related expenses; (3) acquisition-related costs and (4) executive reorganization costs. The Company calculates adjusted net income as net income (loss), adjusted to exclude: (1) amortization of intangible assets (excluding software); (2) share-based compensation expense; (3) certain litigation-related expenses; (4) acquisition-related costs; (5) executive reorganization costs; (6) deferred debt issuance costs write-offs; (7) Tax Receivable Agreement liability adjustments; and (8) tax effect of non-GAAP adjustments. The Company calculates adjusted basic and diluted net income per share as adjusted net income divided by weighted average basic and diluted shares outstanding, respectively. Please refer to "Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents" located in the financial supplement in this release for further information regarding these adjustments for the periods presented.

Please refer to "Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents" located in the financial supplement in this release for a reconciliation of these non-GAAP metrics to their most directly comparable financial measure stated in accordance with GAAP.

This release includes forward-looking guidance for adjusted EBITDA margin and adjusted gross profit margin. The Company is not able to provide, without unreasonable effort, a reconciliation of the guidance for adjusted EBITDA margin and adjusted gross profit margin to the most directly comparable GAAP measure because the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments included in the most directly comparable GAAP measure that would be necessary for such reconciliations, including (a) costs related to potential debt or equity transactions and (b) other non-recurring expenses that cannot reasonably be estimated in advance. These adjustments are inherently variable and uncertain and depend on various factors that are beyond the Company's control and as a result it is also unable to predict their probable significance. Therefore, because management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results in accordance with GAAP, it is unable to provide a reconciliation of the non-GAAP financial measures included in its fiscal year 2026 guidance.


CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except per share and share data)
(Unaudited)

  December 31,
2025
  December 31,
2024
Assets      
Current Assets:      
Cash and cash equivalents $ 318,731     $ 585,967  
Accounts receivable, net of allowances of $18,123 and $15,859   29,013       14,934  
Inventory   60,215       75,165  
Prepaid expenses and other current assets   62,387       13,647  
Total current assets   470,346       689,713  
Property and equipment, net   1,422       1,442  
Intangible assets, net   847,821       899,549  
Goodwill   168,300       168,300  
Deferred tax assets   46        
Other assets   9,552       8,719  
Total assets $ 1,497,487     $ 1,767,723  
       
Liabilities and stockholders’ equity      
Current Liabilities:      
Accounts payable $ 8,117     $ 10,423  
Accrued expenses and other current liabilities   85,304       35,639  
Current portion of long-term debt         6,750  
Current portion of Related Party payable pursuant to Tax Receivable Agreement   9,206       11,842  
Total current liabilities   102,627       64,654  
Long-term debt   352,290       643,712  
Deferred tax liabilities   5,283       5,164  
Related Party payable pursuant to Tax Receivable Agreement   155,858       177,469  
Other liabilities   2,039       2,322  
Total liabilities   618,097       893,321  
       
Commitments and Contingencies      
       
Stockholders’ equity:      
Common stock, $0.001 par value per share; 2,000,000,000 shares authorized, 669,076,651 and 664,224,893 shares issued and outstanding as of December 31, 2025 and 2024, respectively   669       664  
Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024, respectively          
Additional paid-in capital   342,345       328,538  
Accumulated other comprehensive loss   (337 )     (765 )
Retained earnings   536,713       545,965  
Total stockholders’ equity   879,390       874,402  
Total liabilities and stockholders’ equity $ 1,497,487     $ 1,767,723  


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(amounts in thousands, except per share and share data)
(Unaudited)

  Three Months Ended
December 31,
  Year Ended
December 31,
    2025       2024       2025       2024  
Net sales $ 105,119     $ 100,741     $ 422,960     $ 422,670  
Cost of sales:              
Cost of product (excluding amortization)   30,957       31,677       119,329       121,038  
Amortization of patented formulations   2,705       2,288       9,985       9,342  
Total cost of sales   33,662       33,965       129,314       130,380  
Gross profit   71,457       66,776       293,646       292,290  
Operating expenses:              
Selling, general, and administrative   65,107       52,869       243,113       181,685  
Amortization of other intangible assets   10,854       10,862       43,582       43,669  
Total operating expenses   75,961       63,731       286,695       225,354  
Operating (loss) income   (4,504 )     3,045       6,951       66,936  
Interest expense   7,551       14,877       41,342       59,585  
Interest income   (2,659 )     (6,312 )     (14,828 )     (25,379 )
Other (income) expense, net:              
Tax Receivable Agreement liability adjustment   (2,666 )     3,915       (12,118 )     3,915  
Other (income) expense, net   (37 )     1,362       (1,268 )     1,903  
Total other (income) expense, net   (2,703 )     5,277       (13,386 )     5,818  
(Loss) income before income taxes   (6,693 )     (10,797 )     (6,177 )     26,912  
Income tax provision (benefit)   6,409       (1,997 )     3,075       7,390  
Net (loss) income $ (13,102 )   $ (8,800 )   $ (9,252 )   $ 19,522  
               
Net (loss) income per share:              
Basic $ (0.02 )   $ (0.01 )   $ (0.01 )   $ 0.03  
Diluted $ (0.02 )   $ (0.01 )   $ (0.01 )   $ 0.03  
               
Weighted average common shares outstanding:              
Basic   668,087,032       663,154,824       666,459,101       661,980,612  
Diluted   668,087,032       663,154,824       666,459,101       665,397,655  
               
Other comprehensive income (loss):              
Unrealized gain (loss) on derivatives, net of income tax effect $ 151     $ 220     $ 428     $ (2,130 )
Total other comprehensive income (loss)   151       220       428       (2,130 )
Comprehensive (loss) income $ (12,951 )   $ (8,580 )   $ (8,824 )   $ 17,392  


CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
(Unaudited)

  Year Ended
December 31,
    2025       2024  
Cash flows from operating activities      
Net (loss) income $ (9,252 )   $ 19,522  
Adjustments to reconcile net (loss) income to net cash provided by operating activities:   67,912       123,546  
Net cash provided by operating activities   58,660       143,068  
Net cash used in investing activities   (12,606 )     (4,891 )
Net cash used in financing activities   (313,290 )     (18,610 )
Net (decrease) increase in cash and cash equivalents   (267,236 )     119,567  
Cash and cash equivalents - beginning of year   585,967       466,400  
Cash and cash equivalents - end of year $ 318,731     $ 585,967  


Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents

(amounts in thousands, except per share and share data)
(Unaudited)

The following tables present a reconciliation of net (loss) income, gross profit and SG&A, as the most directly comparable financial measure stated in accordance with U.S. GAAP, to adjusted EBITDA, adjusted EBITDA margin, adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income and adjusted net income per share for each of the periods presented.

  Three Months Ended
December 31,
  Year Ended
December 31,
    2025       2024       2025       2024  
Reconciliation of Net (Loss) Income to Adjusted EBITDA              
Net (loss) income $ (13,102 )   $ (8,800 )   $ (9,252 )   $ 19,522  
Depreciation and amortization of intangible assets   13,636       13,243       53,912       53,497  
Interest expense, net   4,892       8,565       26,514       34,206  
Income tax provision (benefit)   6,409       (1,997 )     3,075       7,390  
Share-based compensation expense   3,593       2,563       13,285       11,123  
Certain litigation-related expenses(1)   76             9,148        
Acquisition-related costs(2)   23             9,305        
Executive reorganization cost(3)                     12  
Tax Receivable Agreement liability adjustment   (2,666 )     3,915       (12,118 )     3,915  
Adjusted EBITDA $ 12,861     $ 17,489     $ 93,869     $ 129,665  
Adjusted EBITDA margin   12.2 %     17.4 %     22.2 %     30.7 %


  Three Months Ended
December 31,
  Year Ended
December 31,
    2025       2024       2025       2024  
Reconciliation of Gross Profit to Adjusted Gross Profit              
Gross profit $ 71,457     $ 66,776     $ 293,646     $ 292,290  
Amortization of patented formulations   2,705       2,288       9,985       9,342  
Adjusted gross profit $ 74,162     $ 69,064     $ 303,631     $ 301,632  
Adjusted gross profit margin   70.6 %     68.6 %     71.8 %     71.4 %


  Three Months Ended
December 31,
  Year Ended
December 31,
    2025       2024       2025       2024  
Reconciliation of SG&A to Adjusted SG&A              
SG&A $ 65,107     $ 52,869     $ 243,113     $ 181,685  
Share-based compensation expense   (3,593 )     (2,563 )     (13,285 )     (11,123 )
Certain litigation-related expenses(1)   (76 )           (9,148 )      
Acquisition-related costs(2)   (23 )           (9,305 )      
Executive reorganization cost(3)                     (12 )
Adjusted SG&A $ 61,415     $ 50,306     $ 211,375     $ 170,550  


  Three Months Ended
December 31,
  Year Ended
December 31,
    2025       2024       2025       2024  
Reconciliation of Net (Loss) Income to Adjusted Net Income              
Net (loss) income $ (13,102 )   $ (8,800 )   $ (9,252 )   $ 19,522  
Amortization of intangible assets (excluding software)   12,888       12,471       50,715       50,073  
Share-based compensation expense   3,593       2,563       13,285       11,123  
Deferred debt issuance cost write-off(4)               2,573        
Certain litigation-related expenses(1)   76             9,148        
Acquisition-related costs(2)   23             9,305        
Executive reorganization cost(3)                     12  
Tax Receivable Agreement liability adjustment   (2,666 )     3,915       (12,118 )     3,915  
Tax effect of adjustments   4,748       (2,519 )     (12,273 )     (8,932 )
Adjusted net income $ 5,560     $ 7,630     $ 51,383     $ 75,713  
Adjusted net income per share:              
Basic $ 0.01     $ 0.01     $ 0.08     $ 0.11  
Diluted $ 0.01     $ 0.01     $ 0.08     $ 0.11  
Weighted average diluted shares outstanding(5)   669,084,977       667,406,963       667,937,971       665,397,655  


(1) Represents litigation costs related to the Lilien securities class action. The Company considers litigation costs related to the Lilien securities class action, as described in Note 14 to the Company's Annual Report on Form 10-K for the year ended December 31, 2025, to be non-recurring and non-ordinary. While the Company did not adjust for these costs during the year ended December 31, 2024 because the amounts incurred in 2024 were not material, commencing with the three months ended March 31, 2025, the Company has included an adjustment for these costs as a result of the court's denial of the Company's motion to dismiss in February 2025. The Company believes adjusting for such costs provides investors with meaningful information regarding the Company’s core operating performance.
(2) Represents non-recurring and non-ordinary costs related to the acquisition of all of the outstanding capital stock of Purvala Bioscience, Inc. ("Purvala") by Olaplex, Inc. on August 20, 2025.
(3) Represented benefit payments associated with the departure of the Company's Chief Executive Officer that occurred in fiscal year 2023 and Chief Operating Officer that occurred in fiscal year 2022.
(4) Represents the write-off of deferred debt issuance costs associated with the Company's $300.0 million voluntary repayment of outstanding principal on its term loan facility under the Company's credit agreement on May 1, 2025.
(5) Weighted average diluted shares outstanding for the three months and year ended December 31, 2025 and for the three months ended December 31, 2024 differ from the GAAP presentation on the Company's Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income due to the Company being in a loss position on an unadjusted basis.

 
Contacts:

Investors:

Michael Oriolo
Vice President, Investor Relations
michael.oriolo@olaplex.com

Financial Media:

Lisa Bobroff
Vice President, Global Communications & Consumer Engagement
lisa.bobroff@olaplex.com


Olaplex logo

Source: Olaplex Holdings, Inc.